Columbus Circle Investors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Columbus Circle Investors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,200	Closed	-$225K	–	316
2015 Q4	$225K	Buy	+3,200	New	+$218K	﹤0.01%	272

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Columbus Circle Investors's XBI Position: Q1 2016 in Review

Columbus Circle Investors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2016, closing a stake of 3,200 shares — an estimated $225K sold.

Columbus Circle Investors first reported a position in XBI in Q4 2015 and held it in 1 quarter. The position peaked at $225K in Q4 2015. 195 funds tracked by Wall St. Rank hold XBI as of Q1 2016.

Columbus Circle Investors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2016 after selling out during the quarter.
Columbus Circle Investors sold 3,200 State Street SPDR S&P Biotech ETF shares in Q1 2016, an estimated $225K.
Columbus Circle Investors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2015 and held it in 1 quarter.
Columbus Circle Investors's State Street SPDR S&P Biotech ETF position peaked at $225K in Q4 2015.
195 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2016.

Based on Columbus Circle Investors's 13F filing for Q1 2016, filed 3 May 2016.